Navigation Links
Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc.

Therapure will provide fill/finish services to support product development.

Toronto, ON (Vocus) March 29, 2010 -- Therapure Biopharma Inc. today announced a fill/finish contract with Kane Biotech Inc. (V.KNE), a Canadian biotechnology company based in Winnipeg, Manitoba. Under the terms of the agreement, Therapure will provide custom fill/finish services for a key development-stage product for Kane Biotech. Financial terms were not disclosed.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. Biofilms develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the US health care system $20 billion per year.

“Therapure has signed a variety of fill/finish contracts recently, demonstrating the flexibility of our Health Canada licensed facility” said Thomas Wellner, President and CEO of Therapure. "Our agreement with Kane Biotech includes hand-fill services conducted under Good Manufacturing Practices standards," continued Mr. Wellner.

"Therapure was quick to provide a detailed service proposal that clearly indicated they understood our requirements," said Gord Froehlich, President and CEO of Kane. "We look forward to working closely with Therapure as we advance out products through the approval process," Mr. Froehlich concluded.

About Therapure Biopharma Inc.:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market for its clients. Therapure’s Health Canada licensed 130,000 sq. ft. facility, includes manufacturing, research and quality control laboratories and a cGMP warehouse, and is built to U.S. FDA, EMEA, MHRA and Health Canada standards for the aseptic handling and purification of proteins.

For more information, please visit:

Company Contact:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905 286-6204
ceo (at) therapurebio (dot) com


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
2. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
3. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
4. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
5. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
6. PDL BioPharma Announces Two $0.50 Dividends in 2010
7. Seven More Biopharmaceutical Research Companies Join PhRMA
8. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
9. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
10. New Polycarbonate Sign Face Material Eliminates Hot Spots, Optimizes Light Uniformity in LED Back-Lit Signs
11. President Signs Health Reform Bill that Aids Small Business
Post Your Comments:
(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, ... interesting show that delves into an array of issues that are presently affecting Americans. ... from open dialogue, this show is changing the subjects consumers focus on, one episode ...
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)... ) ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
Breaking Medicine Technology: